68 results
8-K
EX-99.2
ELDN
Eledon Pharmaceuticals Inc
7 May 24
Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
7:15am
the study because of hair loss and fatigue, viral infection, and rejection, respectively. There have been no cases of graft loss or death. The company plans
8-K
EX-99.2
b6e90lkrrgodxgffxuu
2 Nov 23
Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
4:30pm
8-K
EX-99.1
4hwuuxwalq 27l6k
2 Nov 23
Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
4:30pm
8-K
EX-10.1
ry3bm2q84
21 Jun 23
Departure of Directors or Certain Officers
7:51pm
8-K
29zq141noumi73pwr
21 Jun 23
Departure of Directors or Certain Officers
7:51pm
8-K
EX-99.2
iim5s5gz1xbpdt
31 May 22
Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart
6:38am